TN2014000145A1 - Pharmaceutical formulations - Google Patents

Pharmaceutical formulations

Info

Publication number: TN2014000145A1
Authority: TN; Tunisia
Prior art keywords: pharmaceutical formulations; formulations; methylsulfonamido; pyrazol; propan
Prior art date: 2011-11-23

Application number

TNP2014000145A

Other languages

English (en)

Inventor

Daya Verma

Yogita Krishnamachari

Xiaohong Shen

Hanchen Lee

Ping Li

Rajinder Singh

Laychoo Tan

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-11-23

Filing date

2014-04-08

Publication date

2015-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47501412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2014000145(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-04-08 Application filed by Novartis Ag filed Critical Novartis Ag

2015-09-30 Publication of TN2014000145A1 publication Critical patent/TN2014000145A1/en

Links

239000008194 pharmaceutical composition Substances 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
CMJCXYNUCSMDBY-ZDUSSCGKSA-N lgx818 Chemical compound COC(=O)N[C@@H](C)CNC1=NC=CC(C=2C(=NN(C=2)C(C)C)C=2C(=C(NS(C)(=O)=O)C=C(Cl)C=2)F)=N1 CMJCXYNUCSMDBY-ZDUSSCGKSA-N 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Inorganic Chemistry (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TNP2014000145A 2011-11-23 2014-04-08 Pharmaceutical formulations TN2014000145A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161563229P	2011-11-23	2011-11-23
PCT/US2012/066185 WO2013078264A1 (fr)	2011-11-23	2012-11-21	Formulations pharmaceutiques

Publications (1)

Publication Number	Publication Date
TN2014000145A1 true TN2014000145A1 (en)	2015-09-30

Family

ID=47501412

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2014000145A TN2014000145A1 (en)	2011-11-23	2014-04-08	Pharmaceutical formulations

Country Status (38)

Country	Link
US (4)	US9387208B2 (fr)
EP (2)	EP3449911B8 (fr)
JP (2)	JP6216325B2 (fr)
KR (1)	KR102091295B1 (fr)
CN (2)	CN103945831A (fr)
AR (1)	AR088936A1 (fr)
AU (1)	AU2012340759C1 (fr)
BR (1)	BR112014011981B8 (fr)
CA (1)	CA2856406C (fr)
CL (1)	CL2014001337A1 (fr)
CO (1)	CO6940426A2 (fr)
CY (1)	CY1121421T1 (fr)
DK (1)	DK2782557T3 (fr)
EA (1)	EA025389B1 (fr)
EC (1)	ECSP23034537A (fr)
ES (2)	ES2695099T3 (fr)
GT (1)	GT201400100A (fr)
HR (1)	HRP20181896T1 (fr)
HU (1)	HUE040370T2 (fr)
IL (1)	IL232305B (fr)
JO (1)	JO3493B1 (fr)
LT (1)	LT2782557T (fr)
MA (1)	MA35716B1 (fr)
MX (1)	MX353446B (fr)
MY (1)	MY172729A (fr)
PE (1)	PE20141994A1 (fr)
PH (1)	PH12014501157A1 (fr)
PL (1)	PL2782557T3 (fr)
PT (1)	PT2782557T (fr)
RS (1)	RS58048B1 (fr)
SG (1)	SG11201401260QA (fr)
SI (1)	SI2782557T1 (fr)
SM (1)	SMT201800595T1 (fr)
TN (1)	TN2014000145A1 (fr)
TW (1)	TWI649098B (fr)
UA (1)	UA115039C2 (fr)
WO (1)	WO2013078264A1 (fr)
ZA (1)	ZA201402418B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3002B1 (ar)	2009-08-28	2016-09-05	Irm Llc	مركبات و تركيبات كمثبطات كيناز بروتين
CN108542906A (zh)	2011-11-11	2018-09-18	诺华股份有限公司	治疗增生性疾病的方法
ES2695099T3 (es)	2011-11-23	2019-01-02	Array Biopharma Inc	Formulaciones farmacéuticas
MX376083B (es)	2015-06-04	2025-03-07	Pfizer	Formas de dosificacion solidas de palbociclib.
RU2615986C1 (ru) *	2016-02-25	2017-04-12	Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм")	Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения
US10449195B2 (en)	2016-03-29	2019-10-22	Shenzhen Pharmacin Co., Ltd.	Pharmaceutical formulation of palbociclib and a preparation method thereof
MX387795B (es)	2016-06-03	2025-03-19	Array Biopharma Inc	Combinaciones farmaceuticas.
CN106000220A (zh) *	2016-06-30	2016-10-12	东华大学	一种含化学试剂的有机溶剂崩解片的制备方法与应用
CN114306245A (zh)	2020-09-29	2022-04-12	深圳市药欣生物科技有限公司	无定形固体分散体的药物组合物及其制备方法
AU2021358394A1 (en)	2020-10-05	2023-04-13	Pierre Fabre Medicament	Combination of encorafenib and binimetinib as adjuvant treatment for resected stage II melanoma
CN114557977A (zh) *	2022-02-16	2022-05-31	北京康立生医药技术开发有限公司	一种治疗肠癌的药物的制备方法、制剂及纯度分析方法
TR2022009483A2 (tr) *	2022-06-08	2023-12-21	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Palbosiklib içeren bir farmasötik bileşim.
WO2025003956A1 (fr)	2023-06-30	2025-01-02	Pfizer Inc.	Formulations d'encorafénib à forte charge médicamenteuse
WO2025262137A1 (fr) *	2024-06-21	2025-12-26	Nanoform Finland Oyj	Formulations comprenant de l'encorafénib nanométrique cristallin

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5475888A (en)	1977-11-29	1979-06-18	Jiyasuko Kk	Surgical laser
US6391636B1 (en)	1994-05-31	2002-05-21	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of raf gene expression
US6358932B1 (en)	1994-05-31	2002-03-19	Isis Pharmaceticals, Inc.	Antisense oligonucleotide inhibition of raf gene expression
US6037136A (en)	1994-10-24	2000-03-14	Cold Spring Harbor Laboratory	Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
CA2231050A1 (fr) *	1995-09-07	1997-03-13	Biovail International Ltd.	Systeme permettant de rendre biodisponibles des agents bioalterants sensiblement non solubles
US5717100A (en)	1995-10-06	1998-02-10	Merck & Co., Inc.	Substituted imidazoles having anti-cancer and cytokine inhibitory activity
AR012634A1 (es)	1997-05-02	2000-11-08	Sugen Inc	Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6514977B1 (en)	1997-05-22	2003-02-04	G.D. Searle & Company	Substituted pyrazoles as p38 kinase inhibitors
PL337020A1 (en)	1997-05-22	2000-07-31	Searle & Co	Substituted pyrazoles as kinase p38 inhibitors
GB9716557D0 (en)	1997-08-06	1997-10-08	Glaxo Group Ltd	Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en)	1997-11-07	2000-02-08	Amgen Inc.	Substituted pyridine compounds and methods of use
US6204467B1 (en)	1998-03-24	2001-03-20	Ford Global Technologies, Inc.	Method and apparatus for resistive welding
US7351834B1 (en)	1999-01-13	2008-04-01	Bayer Pharmaceuticals Corporation	ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6316435B2 (en)	1999-02-24	2001-11-13	Supergen, Inc.	Combination therapy for lymphoproliferative diseases
EP2415462A1 (fr)	1999-12-23	2012-02-08	Mayne Pharma International Pty Ltd.	Compositions pharmaceutiques ameliorées pour médicaments peu solubles
PE20020354A1 (es)	2000-09-01	2002-06-12	Novartis Ag	Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1456180B1 (fr)	2001-12-21	2007-10-03	Vernalis (Cambridge) Limited	3-(2,4)dihydroxyphenyl-4-phenylpyrazoles et leur utilisation medicale
AU2002350719A1 (en) *	2002-11-29	2004-06-23	Janssen Pharmaceutica N.V.	Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EP1706400A1 (fr)	2004-01-09	2006-10-04	Novartis AG	Derives de phenyl- 4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl¨-amine utilises comme inhibiteurs du recepteur igf-1r
JP4688876B2 (ja)	2004-06-10	2011-05-25	アイアールエム・リミテッド・ライアビリティ・カンパニー	タンパク質キナーゼ阻害剤としての化合物および組成物
JP5178515B2 (ja)	2005-08-12	2013-04-10	シンタファーマシューティカルズコーポレーション	Ｈｓｐ９０活性を調節するピラゾール化合物
KR20080037732A (ko)	2005-08-22	2008-04-30	노파르티스 아게	ｐＨ-의존성 약물, ｐＨ 개질제 및 지연제를 포함하는제약학적 조성물
US20080242667A1 (en)	2005-08-26	2008-10-02	Smithkline Beecham Corporation	Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases
PE20070335A1 (es)	2005-08-30	2007-04-21	Novartis Ag	Benzimidazoles sustituidos y metodos para su preparacion
EP2024353A2 (fr)	2006-03-16	2009-02-18	Pfizer Products Inc.	Pyrazoles
EP2013218A2 (fr)	2006-04-17	2009-01-14	Arqule, Inc.	Inhibiteurs raf et leurs utilisations
WO2008042639A1 (fr)	2006-10-02	2008-04-10	Irm Llc	Composés et compositions utilisés en tant qu'inhibiteurs de protéine kinase
WO2008045627A2 (fr)	2006-10-06	2008-04-17	Irm Llc	Inhibiteurs de la protéine kinase et procédés pour utiliser ceux-ci
AU2007316558A1 (en)	2006-11-09	2008-05-15	Abbott Gmbh & Co. Kg	Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
US20090022789A1 (en) *	2007-07-18	2009-01-22	Supernus Pharmaceuticals, Inc.	Enhanced formulations of lamotrigine
BRPI0815042A2 (pt)	2007-08-01	2015-02-10	Pfizer	Compostos de pirazol
UA100865C2 (ru) *	2007-10-19	2013-02-11	Эбботт Гмбх Унд Ко. Кг	Твердый дисперсный продукт лекарственных средств на основе n-арилмочевины
RU2492170C9 (ru)	2007-11-14	2013-12-27	Орто-Макнейл-Янссен Фармасьютикалз, Инк.	Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2
WO2009100176A2 (fr)	2008-02-07	2009-08-13	Abbott Laboratories	Forme pharmaceutique pour administration orale d’un inhibiteur de tyrosine kinase
AU2009227013B2 (en)	2008-03-21	2013-01-10	Novartis Ag	Novel heterocyclic compounds and uses therof
UA103319C2 (en)	2008-05-06	2013-10-10	Глаксосмитклайн Ллк	Thiazole- and oxazole-benzene sulfonamide compounds
SI2324008T1 (sl)	2008-07-24	2012-08-31	Nerviano Medical Sciences Srl	3,4-diarilpirazoli kot protein-kinazni inhibitorji
JP2011529504A (ja)	2008-07-28	2011-12-08	ギリアードサイエンシーズ，インコーポレイテッド	シクロアルキリデンヒストン脱アセチル化酵素阻害剤化合物およびヘテロシクロアルキリデンヒストン脱アセチル化酵素阻害剤化合物
AR073700A1 (es)	2008-09-29	2010-11-24	Boehringer Ingelheim Int	Heterociclos y composiciones farmaceuticas para usarse en el tratamiento de cancer, infecciones y enfermedades autoinmunitarias
ES2598178T5 (es) *	2008-10-07	2023-12-26	Kudos Pharm Ltd	Formulación farmacéutica 514
WO2010056662A1 (fr)	2008-11-11	2010-05-20	University Of Washington	Signalisation de wnt-bêta-caténine dans le mélanome
US8524707B2 (en)	2008-12-19	2013-09-03	Nerviano Medical Sciences S.R.L.	Bicyclic pyrazoles as protein kinase inhibitors
AR075180A1 (es) *	2009-01-29	2011-03-16	Novartis Ag	Formulaciones orales solidas de una pirido-pirimidinona
WO2010100127A1 (fr)	2009-03-04	2010-09-10	Novartis Ag	Dérivés d'imidazole disubstitués en tant que modulateurs de la protéine kinase raf
TWI532484B (zh) *	2009-06-08	2016-05-11	艾伯維有限公司	包含凋亡促進劑之固態分散劑
ES2570756T3 (es)	2009-06-15	2016-05-20	Nerviano Medical Sciences Srl	Derivados pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa
KR101256018B1 (ko)	2009-08-20	2013-04-18	한국과학기술연구원	단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
US8242260B2 (en)	2009-08-28	2012-08-14	Novartis Ag	Compounds and compositions as protein kinase inhibitors
JO3002B1 (ar)	2009-08-28	2016-09-05	Irm Llc	مركبات و تركيبات كمثبطات كيناز بروتين
WO2011092088A1 (fr)	2010-01-27	2011-08-04	Nerviano Medical Sciences S.R.L.	Dérivés sulfonamido des 3,4-diarylpyrazones comme inhibiteurs des protéines kinases
JP6155187B2 (ja)	2010-03-30	2017-06-28	ヴァーセオンコーポレイション	トロンビンの阻害剤としての多置換芳香族化合物
WO2012016993A1 (fr)	2010-08-03	2012-02-09	Nerviano Medical Sciences S.R.L.	Dérivés de composés de pyrazolophényl-benzènesulfonamide et leur utilisation en tant qu'agents antitumoraux
PL2688572T3 (pl)	2011-03-21	2017-08-31	Valcuria Ab	Kompozycja farmaceutyczna zawierająca inhibitor hdac i steroid oraz jej stosowanie
ES2595407T3 (es)	2011-06-14	2016-12-29	Novartis Ag	Combinación de panobinostat y ruxolitinib en el tratamiento de cáncer, tal como una neoplasia mieloproliferativa
ES2695099T3 (es)	2011-11-23	2019-01-02	Array Biopharma Inc	Formulaciones farmacéuticas
AU2013343425A1 (en)	2012-11-08	2015-06-11	Novartis Ag	Pharmaceutical combination comprising a B-Raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases

2012
- 2012-11-21 ES ES12809882T patent/ES2695099T3/es active Active
- 2012-11-21 LT LTEP12809882.9T patent/LT2782557T/lt unknown
- 2012-11-21 JP JP2014543550A patent/JP6216325B2/ja active Active
- 2012-11-21 KR KR1020147013457A patent/KR102091295B1/ko active Active
- 2012-11-21 PE PE2014000678A patent/PE20141994A1/es active IP Right Grant
- 2012-11-21 PT PT12809882T patent/PT2782557T/pt unknown
- 2012-11-21 SG SG11201401260QA patent/SG11201401260QA/en unknown
- 2012-11-21 ES ES18188984T patent/ES3037966T3/es active Active
- 2012-11-21 HU HUE12809882A patent/HUE040370T2/hu unknown
- 2012-11-21 EP EP18188984.1A patent/EP3449911B8/fr active Active
- 2012-11-21 SI SI201231455T patent/SI2782557T1/sl unknown
- 2012-11-21 EA EA201491007A patent/EA025389B1/ru unknown
- 2012-11-21 AU AU2012340759A patent/AU2012340759C1/en active Active
- 2012-11-21 BR BR112014011981A patent/BR112014011981B8/pt active IP Right Grant
- 2012-11-21 MY MYPI2014000970A patent/MY172729A/en unknown
- 2012-11-21 PL PL12809882T patent/PL2782557T3/pl unknown
- 2012-11-21 WO PCT/US2012/066185 patent/WO2013078264A1/fr not_active Ceased
- 2012-11-21 CN CN201280056985.9A patent/CN103945831A/zh active Pending
- 2012-11-21 US US14/359,121 patent/US9387208B2/en active Active
- 2012-11-21 RS RS20181376A patent/RS58048B1/sr unknown
- 2012-11-21 MX MX2014006278A patent/MX353446B/es active IP Right Grant
- 2012-11-21 CA CA2856406A patent/CA2856406C/fr active Active
- 2012-11-21 AR ARP120104373A patent/AR088936A1/es not_active Application Discontinuation
- 2012-11-21 HR HRP20181896TT patent/HRP20181896T1/hr unknown
- 2012-11-21 EP EP12809882.9A patent/EP2782557B1/fr active Active
- 2012-11-21 DK DK12809882.9T patent/DK2782557T3/en active
- 2012-11-21 UA UAA201403227A patent/UA115039C2/uk unknown
- 2012-11-21 SM SM20180595T patent/SMT201800595T1/it unknown
- 2012-11-21 CN CN201610104236.9A patent/CN105708819B/zh active Active
- 2012-11-22 JO JOP/2012/0353A patent/JO3493B1/ar active
- 2012-11-22 TW TW101143808A patent/TWI649098B/zh active
2014
- 2014-04-02 ZA ZA2014/02418A patent/ZA201402418B/en unknown
- 2014-04-08 TN TNP2014000145A patent/TN2014000145A1/en unknown
- 2014-04-28 CO CO14090466A patent/CO6940426A2/es unknown
- 2014-04-28 IL IL232305A patent/IL232305B/en active IP Right Grant
- 2014-05-15 MA MA37033A patent/MA35716B1/fr unknown
- 2014-05-22 PH PH12014501157A patent/PH12014501157A1/en unknown
- 2014-05-22 CL CL2014001337A patent/CL2014001337A1/es unknown
- 2014-05-23 GT GT201400100A patent/GT201400100A/es unknown
2016
- 2016-06-10 US US15/179,190 patent/US9763941B2/en active Active
2017
- 2017-03-07 US US15/452,239 patent/US10258622B2/en active Active
- 2017-09-22 JP JP2017182214A patent/JP2018035171A/ja active Pending
2018
- 2018-03-14 US US15/921,306 patent/US10561654B2/en active Active
- 2018-11-20 CY CY20181101222T patent/CY1121421T1/el unknown
2023
- 2023-05-15 EC ECSENADI202334537A patent/ECSP23034537A/es unknown

Also Published As

Publication number	Publication date
HUE040370T2 (hu)	2019-03-28
IL232305A0 (en)	2014-06-30
CO6940426A2 (es)	2014-05-09
AR088936A1 (es)	2014-07-16
EP3449911B8 (fr)	2025-07-23
JO3493B1 (ar)	2020-07-05
US9387208B2 (en)	2016-07-12
KR20140095500A (ko)	2014-08-01
KR102091295B1 (ko)	2020-03-19
HK1197024A1 (en)	2015-01-02
SMT201800595T1 (it)	2019-01-11
BR112014011981A2 (pt)	2017-05-30
TW201328722A (zh)	2013-07-16
UA115039C2 (uk)	2017-09-11
ES3037966T3 (en)	2025-10-08
SG11201401260QA (en)	2014-07-30
EP2782557B1 (fr)	2018-09-12
CA2856406C (fr)	2020-06-23
JP2015501808A (ja)	2015-01-19
CN105708819A (zh)	2016-06-29
EP2782557A1 (fr)	2014-10-01
EP3449911B1 (fr)	2025-06-18
LT2782557T (lt)	2018-12-27
US20140309250A1 (en)	2014-10-16
BR112014011981A8 (pt)	2018-07-31
RS58048B1 (sr)	2019-02-28
CN105708819B (zh)	2020-12-29
JP6216325B2 (ja)	2017-10-18
ECSP23034537A (es)	2023-08-31
PH12014501157B1 (en)	2014-08-11
AU2012340759C1 (en)	2019-11-28
TWI649098B (zh)	2019-02-01
PL2782557T3 (pl)	2019-03-29
PH12014501157A1 (en)	2014-08-11
SI2782557T1 (sl)	2019-02-28
NZ623628A (en)	2016-05-27
ES2695099T3 (es)	2019-01-02
EA025389B1 (ru)	2016-12-30
CL2014001337A1 (es)	2014-10-24
CA2856406A1 (fr)	2013-05-30
GT201400100A (es)	2017-09-28
MX2014006278A (es)	2014-07-09
MX353446B (es)	2018-01-12
US20190054086A1 (en)	2019-02-21
IL232305B (en)	2019-06-30
MA35716B1 (fr)	2014-12-01
US10561654B2 (en)	2020-02-18
ZA201402418B (en)	2015-03-25
MY172729A (en)	2019-12-11
EA201491007A1 (ru)	2014-08-29
PT2782557T (pt)	2018-11-26
WO2013078264A1 (fr)	2013-05-30
PE20141994A1 (es)	2014-12-24
US10258622B2 (en)	2019-04-16
AU2012340759A1 (en)	2014-05-29
BR112014011981B8 (pt)	2022-07-19
JP2018035171A (ja)	2018-03-08
US9763941B2 (en)	2017-09-19
US20160279129A1 (en)	2016-09-29
AU2012340759B2 (en)	2016-04-28
EP3449911A1 (fr)	2019-03-06
BR112014011981B1 (pt)	2020-11-17
US20170202837A1 (en)	2017-07-20
CY1121421T1 (el)	2020-05-29
HRP20181896T1 (hr)	2019-02-22
DK2782557T3 (en)	2018-12-10
CN103945831A (zh)	2014-07-23

Publication	Publication Date	Title
ECSP23034537A (es)	2023-08-31	Formulaciones farmaceuticas
PH12017501306A1 (en)	2019-02-27	Inhibitors of histone demethylases
PH12014500987A1 (en)	2014-06-16	Neprilysin inhibitors
EA033689B9 (ru)	2020-04-29	Ингибиторы g12c kras
EA201400412A1 (ru)	2014-08-29	ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
MX2014008020A (es)	2014-12-08	Compuestos de fenil carbamato para uso en la prevencion o tratamiento de epilepsia.
MY163394A (en)	2017-09-15	Substituted aminobutyric derivates as neprilysin inhibitors
EA201500298A1 (ru)	2015-08-31	Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
UA109661C2 (uk)	2015-09-25	Фармацевтична композиція співкристалів трамадолу і коксибів
MX392150B (es)	2025-03-21	Moduladores de receptores canabinoides.
PH12016501462A1 (en)	2017-02-06	Neprilysin inhibitors
WO2013061004A8 (fr)	2014-04-17	Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
EP3207928A4 (fr)	2018-03-14	Préparation composite, contenant un nouveau dérivé de l'acide 3-(4- (benzyloxy)phényl)hex-4-inoïque et un autre principe actif, et destinée à prévenir ou traiter les maladies métaboliques
WO2013040227A3 (fr)	2013-07-25	Composés thérapeutiques
MX342898B (es)	2016-10-18	Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol.
PH12014502541A1 (en)	2015-01-21	5-amino [1,4] thiazines as bace 1 inhibitors
MX2018001979A (es)	2019-04-25	(s,e) -3- (6-aminopiridin-3-il) -n- ( (5- (4- (3-fluoruro-3 metilpirrolidin-1-carbonil) fenil) -7- (4 fluorofenil) benzofuran-2-il)metil)acrilamida para el tratamiento del cancer.
EA201690673A1 (ru)	2016-08-31	Комбинированная терапия лахинимодом для лечения рассеянного склероза
EA201390619A1 (ru)	2013-11-29	3-замещенные 6-(пиридинилметокси)пирролопиридиновые соединения
TH171493A (th)	2017-12-21	สูตรผสมทางเภสัชกรรม
TH104292B (th)	2024-10-28	สูตรผสมทางเภสัชกรรม
SA515360233B1 (ar)	2017-11-12	مثبطات إنزيمات هستون ديميثيلاز
MX2011003390A (es)	2014-09-02	Compuestos y composiciones útiles en el tratamiento de enfermedades cardiacas con efectos secundarios reducidos.
EA201390464A1 (ru)	2013-08-30	Способ сухой обработки атазанавира